$EPIX
ESSA Pharma Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024010767 Filed on August 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue $62.77K
YoY Change
Gross Profit -$62.77K
YoY Change
Gross Profit Margin
Selling, General & Admin $3.174M
YoY Change 12.8%
% of Gross Profit
Research & Development $5.464M
YoY Change -12.87%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.638M
YoY Change -3.07%
Operating Profit -$8.701M
YoY Change -2.37%
Interest Expense $1.405M
YoY Change -12.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.234M
YoY Change -0.89%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.234M
YoY Change -0.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 44.37M 44.36M
Diluted Shares Outstanding 44.37M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.7M
YoY Change -14.28%
Cash & Equivalents $103.7M $85.99M
Short-Term Investments $44.71M
Other Short-Term Assets $1.213M
YoY Change 76.27%
Inventory
Prepaid Expenses $636.5K $1.213M
Receivables $183.6K
Other Receivables $0.00
Total Short-Term Assets $127.6M $132.1M
YoY Change -14.27% -13.83%
LONG-TERM ASSETS
Property, Plant & Equipment $318.3K
YoY Change 234.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $257.0K
YoY Change -2.9%
Total Long-Term Assets $552.4K $575.3K
YoY Change 69.85% 59.87%
TOTAL ASSETS
Total Short-Term Assets $127.6M $132.1M
Total Long-Term Assets $552.4K $575.3K
Total Assets $128.1M $132.7M
YoY Change -14.09% -13.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.404M $1.908M
YoY Change 18.5% -6.95%
Accrued Expenses $171.7K $869.1K
YoY Change -79.7% 12.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.301M $3.575M
YoY Change -5.55% 4.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $229.7K
YoY Change
Total Long-Term Liabilities $229.7K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.301M $3.575M
Total Long-Term Liabilities $229.7K
Total Liabilities $3.506M $3.805M
YoY Change 0.32% 11.65%
SHAREHOLDERS EQUITY
Retained Earnings -$208.0M -$201.6M
YoY Change 15.9% 15.9%
Common Stock $279.9M $279.8M
YoY Change 0.61% 0.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.6M $128.9M
YoY Change
Total Liabilities & Shareholders Equity $128.1M $132.7M
YoY Change -14.09% -13.66%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$7.234M
YoY Change -0.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.745M
YoY Change 72.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $23.48K
YoY Change -100.95%
Cash From Investing Activities $23.48K
YoY Change -100.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.58K
YoY Change -172.02%
NET CHANGE
Cash From Operating Activities -5.745M
Cash From Investing Activities 23.48K
Cash From Financing Activities 25.58K
Net Change In Cash -5.696M
YoY Change -2.34%
FREE CASH FLOW
Cash From Operating Activities -$5.745M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001633932
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#ShortTermInvestments
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44368959
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44100838
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37410
dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1250703
dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
dei City Area Code
CityAreaCode
778
dei Local Phone Number
LocalPhoneNumber
331-0962
dei Security12b Title
Security12bTitle
Common Shares
dei Trading Symbol
TradingSymbol
EPIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44368959
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85985140
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33701912
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
44709312
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
114374489
CY2024Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
183585
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
135057
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1213018
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
585420
CY2024Q2 us-gaap Assets Current
AssetsCurrent
132091055
CY2023Q3 us-gaap Assets Current
AssetsCurrent
148796878
CY2024Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
256977
CY2023Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
257245
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
318275
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68008
CY2024Q2 us-gaap Assets
Assets
132666307
CY2023Q3 us-gaap Assets
Assets
149122131
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3462622
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3414743
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112435
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80328
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3575057
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3495071
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
229707
CY2024Q2 us-gaap Liabilities
Liabilities
3804764
CY2023Q3 us-gaap Liabilities
Liabilities
3495071
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44368959
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44100838
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
279752182
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
278161537
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52858691
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49047280
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2100367
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2120398
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-201648963
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179461359
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
128861543
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
145627060
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132666307
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149122131
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5464123
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6271186
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17018874
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16096299
CY2023Q2 epix Financing Costs
FinancingCosts
1527
epix Financing Costs
FinancingCosts
5821
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3174195
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2639381
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9707565
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8889192
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
8638318
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
8912094
us-gaap Operating Expenses
OperatingExpenses
26726439
us-gaap Operating Expenses
OperatingExpenses
24991312
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3589
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-827
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2074
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9944
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1408160
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1614048
us-gaap Interest And Other Income
InterestAndOtherIncome
4536761
us-gaap Interest And Other Income
InterestAndOtherIncome
3881974
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7233747
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7298873
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22187604
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21099394
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7233747
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7298873
us-gaap Net Income Loss
NetIncomeLoss
-22187604
us-gaap Net Income Loss
NetIncomeLoss
-21100994
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
656
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
42689
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
20031
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
13001
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7233091
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7256184
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22167573
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21087993
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44365505
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44365505
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44092374
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44092374
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44243638
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44243638
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44085941
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44085941
us-gaap Profit Loss
ProfitLoss
-22187604
us-gaap Profit Loss
ProfitLoss
-21100994
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
67877
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91341
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
666548
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
482843
us-gaap Accretion Expense
AccretionExpense
24572
us-gaap Accretion Expense
AccretionExpense
5821
us-gaap Investment Income Net
InvestmentIncomeNet
415698
us-gaap Investment Income Net
InvestmentIncomeNet
81350
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
661
us-gaap Share Based Compensation
ShareBasedCompensation
4536217
us-gaap Share Based Compensation
ShareBasedCompensation
4161772
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
48528
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
127082
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
627330
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1122248
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
47879
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1118449
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-80902
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19350065
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15293299
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
27767609
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
258307260
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
98532441
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
255044760
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
70764832
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3262500
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
820326
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
45513
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
50291
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
0
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
104800
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
865839
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-54509
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2622
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
824
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52283228
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18609484
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33701912
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57076475
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85985140
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38466991
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
318144
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
167118478
CY2022Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50291
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1563608
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6712455
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
162019922
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1437091
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7119354
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
156337659
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1161073
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7256184
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
150242548
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
145627060
CY2023Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
163306
CY2023Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
33353
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
803418
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5944198
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
140682939
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
643603
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1132601
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8990284
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
133468859
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13417
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
12160
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2600198
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7233091
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
128861543
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the Suite 3500, The Stack, 1133 Melville Street, Vancouver, BC, V6E 4E5. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The</span> <span style="font-weight:normal;">Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (“NTD”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As of June 30, 2024, no products are in commercial production or use.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as of the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Estimates and assumptions are reviewed quarterly.</p>
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
43795228
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23376
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
937460
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
44709312
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
44700000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
114400000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23376
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
43248
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
410678
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
24839
CY2024Q2 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
495768
CY2023Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
181835
CY2024Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
306572
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
378746
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1213018
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
585420
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1908037
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2028265
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
869149
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
845730
CY2024Q2 epix Employee Compensation And Vacation Accruals Current
EmployeeCompensationAndVacationAccrualsCurrent
685436
CY2023Q3 epix Employee Compensation And Vacation Accruals Current
EmployeeCompensationAndVacationAccrualsCurrent
540748
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3462622
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3414743
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68008
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
318144
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
67877
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
318275
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
80328
epix Operating Lease Liabilities Addition
OperatingLeaseLiabilitiesAddition
318144
us-gaap Operating Lease Cost
OperatingLeaseCost
56330
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
342142
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112435
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
229707
CY2024Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1025
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
118292
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
132887
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
136873
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11719
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
399771
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
57629
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
342142
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8112774
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1728750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.81
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
251427
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
283229
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.92
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9306868
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.67
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6901374
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.84
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9306868
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1728750
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.82
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2927477
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.11
epix Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
7477
epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired
-42.80
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2920000
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.00
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2920000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 epix Cash Canada Deposit Insurance Corporation Insured Amount
CashCanadaDepositInsuranceCorporationInsuredAmount
100000
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2024Q2 epix Working Capital
WorkingCapital
128515998
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-010767-index-headers.html Edgar Link pending
0001558370-24-010767-index.html Edgar Link pending
0001558370-24-010767.txt Edgar Link pending
0001558370-24-010767-xbrl.zip Edgar Link pending
epix-20240630.xsd Edgar Link pending
epix-20240630x10q.htm Edgar Link pending
epix-20240630x10q001.jpg Edgar Link pending
epix-20240630x10q003.jpg Edgar Link pending
epix-20240630x10q004.jpg Edgar Link pending
epix-20240630xex31d1.htm Edgar Link pending
epix-20240630xex31d2.htm Edgar Link pending
epix-20240630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
epix-20240630_cal.xml Edgar Link unprocessable
epix-20240630_def.xml Edgar Link unprocessable
epix-20240630_lab.xml Edgar Link unprocessable
epix-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
epix-20240630x10q_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending